PHAXIAM Therapeutics

📍 LYON, France🗓 Founded 2004👥 84 employees💰 Last funded Jan 2018
Biotechnology🌐 phaxiam.com
Website LinkedIn
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2004
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
2
Frequently asked questions
Who invested in PHAXIAM Therapeutics?
PHAXIAM Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers.
When did PHAXIAM Therapeutics last raise funding?
The most recent investment in PHAXIAM Therapeutics recorded on gritt.io was in January 2018.
When was PHAXIAM Therapeutics founded?
PHAXIAM Therapeutics was founded in 2004.
What industry is PHAXIAM Therapeutics in?
PHAXIAM Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is PHAXIAM Therapeutics based?
PHAXIAM Therapeutics is headquartered in LYON, France.